Prospective screening of dyspeptic patients by Helicobacter pylori serology

Patel, Praful; Mendall, Michael A.; Khulusi, S.; Lloyd, R. S.; Jazrawi, R. P.; Maxwell, J. D.; Northfield, T. C.

doi:10.1016/s0140-6736(95)92340-3

Cited by 147 publications

(96 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…21 The most that can be said is that in patients referred for investigation, serology testing alone rather than endoscopy in those testing H. pylori-negative appears to be equally effective. However, these results need to be confirmed both by an RCT and in less selected groups of patients recruited from primary care.…”

Section: Discussionmentioning

confidence: 99%

“…20 However, some recent evidence suggests that knowledge of H. pylori status can reassure patients and may be a cost-effective strategy. 21 Test-and-treat PUD is cured by H. pylori eradication, and there are now safe and relatively inexpensive regimens that effectively treat this organism. 22 A logical extension of H. pylori screening is therefore to simply treat the infection if it is present, as recommended by a recent European Helicobacter pylori Study Group consensus statement, rather than referring this group of patients for endoscopy.…”

Section: Screening For H Pylorimentioning

confidence: 99%

“…Patel and colleagues 21 conducted a prospective cohort study with historical controls, in which 183 patients, aged under 45 years, were recruited via an open access endoscopy clinic; 70 tested positive for H. pylori using the Helico G ® serology test with a cut-off of 6.3 U/ml. These 70 patients were compared with 70 referred for endoscopy who tested negative for H. pylori but had been endoscoped in the previous months.…”

Section: Description Of Studiesmentioning

confidence: 99%

See 2 more Smart Citations

The management of dyspepsia: a systematic review.

Delaney

Moayyedi²,

Deeks³

et al. 2000

Health Technology Assessment

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK.We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. Competing interests: R Hobbs is a board member of the European Society of Primary Care Gastroenterology, and has received sponsorship for travel and honoraria from a number of biotechnology and pharmaceutical companies for plenary talks and attendance at major scientific congresses and conferences. HTA Published end of 2000This report should be referenced as follows:Delaney B, Moayyedi P, Deeks J, Innes M, Soo S, Barton P, et al. NHS R&D HTA ProgrammeT he NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS.Initially, six HTA panels (pharmaceuticals, acute sector, primary and community care, diagnostics and imaging, population screening, methodology) helped to set the research priorities for the HTA Programme. However, during the past few years there have been a number of changes in and around NHS R&D, such as the establishment of the National Institute for Clinical Excellence (NICE) and the creation of three new research programmes: Service Delivery and Organisation (SDO); New and ...

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Screening For H Pylorimentioning

confidence: 99%

Section: Description Of Studiesmentioning

confidence: 99%

See 1 more Smart Citation

The management of dyspepsia: a systematic review.

Delaney

Moayyedi²,

Deeks³

et al. 2000

Health Technology Assessment

View full text Add to dashboard Cite

show abstract

“…It might therefore be more ef®cient to use H. pylori testing in patient groups with a high prior risk of peptic ulcer disease in order to detect patients suitable for prompt H. pylori treatment or endoscopy. Patients who would bene®t from this approach include, for example, those selected for endoscopy 15 and those with a history of peptic ulcer disease. 16 Several reports have suggested that patients on maintenance therapy with acid-inhibiting drugs might also bene®t, since at least some of them have a history of peptic ulcers.…”

Section: Discussionmentioning

confidence: 99%

Helicobacter pylori treatment instead of maintenance therapy for peptic ulcer disease: the effectiveness of case‐finding in general practice

Wit

Quartero

Numans

1999

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Background: Maintenance therapy with acid‐inhibiting medication is common in general practice. Since the eradication of Helicobacter pylori has become the treatment of choice for peptic ulcer disease, H. pylori treatment could replace maintenance therapy in patients with an ulcer history.Aim: To determine the effectiveness of a full peptic ulcer disease history case‐finding strategy, together with subsequent H. pylori testing and treatment, in discontinuing maintenance therapy.Method: Patients were included from seven general practices, who had been using acid‐inhibiting medication for more than 3 months in the period May 1996–May 1997. Patients with a history of proven peptic ulcer disease were tested, and treated with proton pump inhibitor‐triple therapy if positive. Maintenance therapy was discontinued and restart within 12 months was monitored.Results: Long‐term acid suppression was used by 2.8% of the practice‐populations. A peptic ulcer disease history was found in 18% of the patients, 73% of whom were offered the ‘H. pylori test and treat’ alternative. The majority responded: 92% of the H. pylori‐infected patients were treated, 78% of whom successfully discontinued long‐term medication.Conclusion: Implementing an ‘H. pylori test and treat’ strategy enabled one‐third of the patients with a peptic ulcer disease history to stop maintenance therapy successfully. The strategy contributes to reduction of long‐term drug use, but compliance needs improvement.

show abstract

“…Other infections with spiral organisms have been described (70,71). Antibody to Helicobacter pylori was measured by ELISA in sera of patients and in gastric biopsy specimens (72,73). Colloidal bismuth subcitrate (CBS) combined with tinidazole in patients sensitive to nitroimidazole eradicates most Helicobacter pylori organisms.…”

Section: Helicobacter Pylorimentioning

confidence: 99%

Pathophysiology and modern treatment of ulcer disease (Review)

Holle¹

2010

Int J Mol Med

View full text Add to dashboard Cite

Abstract. This is an overview of the pathophysiological abnormalities of gastroduodenal (GD) ulcers [duodenal ulcer (DU), gastric ulcer (GU) and Dragstedt ulcers (combined DU and GD)], as well as the effects of the different treatments (surgical, medicinal and physiological) described since the introduction of stomach resections. The intention is to demonstrate whether the peptic ulcer diseases are a homogeneous entity with a characteristic pathophysiology or whether they represent the final expression of many heterogeneous causes including impairment of upper gastrointestinal motility. The review also asks whether DU and GU have a common or different pathogenesis and whether ulcers in the stomach might be predominantly due to impaired mucosal resistance and the DU to gastric hypersecretion. The symptoms of both diseases are also compared with the findings in the normal controls.

show abstract

Prospective screening of dyspeptic patients by Helicobacter pylori serology

Cited by 147 publications

References 11 publications

The management of dyspepsia: a systematic review.

The management of dyspepsia: a systematic review.

Helicobacter pylori treatment instead of maintenance therapy for peptic ulcer disease: the effectiveness of case‐finding in general practice

Pathophysiology and modern treatment of ulcer disease (Review)

Contact Info

Product

Resources

About